EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping

B Royer, M Launay, J Ciccolini, L Derain, F Parant, F Thomas, J Guitton

ESMO Open · 2023-06 · 8 (3) · 101577

DOI: 10.1016/j.esmoop.2023.101577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESMO Open, 2023-06. Verfasst von B Royer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon; Univ. Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffo…. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Dihydropyrimidine Dehydrogenase Deficiency. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The chemotherapeutic agent 5-fluorouracil (5-FU) is catabolized by dihydropyrimidine dehydrogenase (DPD), the deficiency of which may lead to severe toxicity or death. Since 2019, DPD deficiency testing, based on uracilemia, is mandatory in France and recommended in Europe before initiating fluoropyrimidine-based regimens. However, it has been recently shown that renal impairment may impact uracil concentration and thus DPD phenotyping. PATIENTS AND METHODS: The impact of renal function on uracilemia and DPD phenotype was studied on 3039 samples obtained from three French centers. We also explored the influence of dialysis and measured glomerular filtration rate (mGFR) on both parameters. Finally, using patients as their own controls, we assessed as to what extent modifications in renal function impacted uracilemia and DPD phenotyping. RESULTS: We observed that uracilemia and DPD-deficient phenotypes increased concomitantly to the severity of renal impairment based on the estimated GFR, independently and more critically than hepatic function. This observation was confirmed with the mGFR. The risk of being classified 'DPD deficient' based on uracilemia was statistically higher in patients with renal impairment or dialyzed if uracilemia was measured before dialysis but not after. Indeed, the rate of DPD deficiency decreased from 86.4% before dialysis to 13.7% after. Moreover, for patients with transient renal impairment, the rate of DPD deficiency dropped dramatically from 83.3% to 16.7% when patients restored their renal function, especially in patients with an uracilemia close to 16 ng/ml. CONCLUSIONS: DPD deficiency testing using uracilemia could be misleading in patients with renal impairment. When possible, uracilemia should be reassessed in case of transient renal impairment. For patients under dialysis, testing of DPD deficiency should be carried out on samples taken after dialysis. Hence, 5-FU therapeutic drug monitoring would be particularly helpful to guide dose adjustments in patients with elevated uracil and renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)Dihydropyrimidine Dehydrogenase DeficiencyHumansAntimetabolites, AntineoplasticFluorouracilUracil

Stichwörter der Autor:innen

DPD phenotypedihydropyrimidine dehydrogenase—DPDfluoropyrimidinemulticentric studyrenal impairmenturacil

Substanzen

Dihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticFluorouracilUracil

Autor:innen und Institutionen

  • Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon; Univ. Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon. Electronic addres…
  • Pôle de Biologie-Pathologie, Hôpital Nord-CHU Saint Etienne, Saint Etienne.
  • SMARTc Unit, Centre de Recherche en Cancérologie de Marseille Inserm U1068 Aix Marseille Université and Assistance Publique Hôpitaux de Marseille, Marseille.
  • Service de Néphrologie, Dialyse, Hypertension et Exploration Fonctionnelle Rénale, Hospices Civils de Lyon, Hôpital E. Herriot, Lyon F-69003; University of Lyon 1; CNRS UMR 5305, Lyon.
  • Laboratoire de Biochimie et Toxicologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite.
  • Laboratoire de Pharmacologie, Institut Claudius Regaud, Inserm CRCT, Université de Toulouse, Toulouse Cedex 9.

Zitieren

APA

Royer, B., Launay, M., Ciccolini, J., Derain, L., Parant, F., Thomas, F., & Guitton, J. (2023). Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. ESMO Open, 8(3), 101577. https://doi.org/10.1016/j.esmoop.2023.101577

Vancouver

Royer B, Launay M, Ciccolini J, Derain L, Parant F, Thomas F, et al. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. ESMO Open. 2023;8(3):101577. doi:10.1016/j.esmoop.2023.101577

BibTeX
@article{Royer2023,
  author = {Royer, B and Launay, M and Ciccolini, J and Derain, L and Parant, F and Thomas, F and Guitton, J},
  title = {Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping},
  journal = {ESMO Open},
  year = {2023},
  volume = {8},
  number = {3},
  pages = {101577},
  doi = {10.1016/j.esmoop.2023.101577}
}
Kostenlos starten →